Sotrovimab: New COVID drug that reduces the risk of hospitalization and death by 79% approved for use in the UK in people aged 12 years and older | UK News

A new drug that can reduce the risk of hospitalization and death due to COVID by 79% has been approved for use in the UK for people aged 12 and up.

Xevudy – also known as sotrovimab – has been given the green light by the Medicines and Healthcare Products Regulatory Agency (MHRA) after being shown to reduce the risk of serious illness in high-risk adults who had COVID symptoms.

The drug was developed by London-based GlaxoSmithKline in collaboration with Vir Biotechnology in California – and the manufacturers say that preclinical data show that the drug “retains activity against key mutations of the new Omicron variant”.

Live COVID updates from the UK and around the world

But the MHRA has said it is too early to confirm this.

George Scangos, Vir CEO, said: “Sotrovimab was deliberately designed with a mutating virus in mind.

“By targeting a highly conserved region of the tip protein that is less likely to mutate, we hoped to address both the current Sars-CoV-2 virus and future variants that we expected would be unavoidable.”

In a statement, the MHRA said: “Like molnupiravir, [Xevudy] has been approved for use in individuals with mild to moderate COVID-19 infection and at least one risk factor for developing serious illness.

“Such risk factors include obesity, older age (over 60 years), diabetes mellitus or heart disease.

MUST CREDIT GSK / Vir Biotechnology Another COVID-19 treatment, Xevudy (sotrovimab), has today been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA), after it was found to be safe and effective in reducing the risk of hospitalization and death in persons with mild to moderate COVID-19 infection who are at increased risk of developing serious illness.
Picture:
The new drug is administered by intravenous infusion over 30 minutes. Photo: GSK / Vir Biotechnology

Unlike molnupiravir, sotrovimab is administered as an intravenous infusion over 30 minutes.

“It is approved for persons aged 12 and over who weigh more than 40 kg.

“It is too early to know if the Omicron variant has any influence on the efficacy of sotrovimab, but the MHRA will work with the company to determine this.”

Dr. June Raine, CEO of MHRA, said: “This is another therapeutic agent that has been shown to be effective in protecting those most vulnerable to COVID-19 and signals another important step forward in our fight. against this devastating disease.

Follow the daily podcast on Apple Podcasts, Google Podcasts, Spotify, Speaker

“Without compromising on quality, security and efficiency, the public can trust that the MHRA has made a robust and thorough assessment of all available data.”

The UK has ordered around 100,000 doses of sotrovimab.

Follow us on Google News

Disclaimers for mcutimes.com

All the information on this website - https://mcutimes.com - is published in good faith and for general information purpose only. mcutimes.com does not make any warranties about the completeness, reliability, and accuracy of this information. Any action you take upon the information you find on this website (mcutimes.com), is strictly at your own risk. mcutimes.com will not be liable for any losses and/or damages in connection with the use of our website.

Give a Comment